Evidence map›Paper›PMID 20377474›Full record

ReviewExpert opinion on drug safety2010

Statin use and cancer risk: a comprehensive review.

Denise M Boudreau, Onchee Yu, Jeanene Johnson

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on drug safety, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 9 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 9 syntheses or guidelines pooled it, 277 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017
    Guideline
  4. Pooled it
  5. Statins for the prevention of dementia.The Cochrane database of systematic reviews · 2016
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Denise M BoudreauGroup Health Research Institute, 1730 Minor Ave, Suite 1600, Seattle, WA 98101, USA. boudreau.d@ghc.org
Onchee Yu
Jeanene Johnson
Kaiser Permanente Washington Health Research Institute · USUniversity of Washington · US

Funding

Commonly Used Medications and Breast Cancer RecurrenceR01CA120562 · NCI · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI BOUDREAU, DENISE M · 2007 to 2011
$2.1M
NCI NIH HHS CA120562NCI NIH HHS R01 CA120562
6 · The paper itself

Abstract

importance of the fieldHMG-CoA inhibitors (statins), a class of drugs that reduce cholesterol, are used to manage and prevent coronary heart disease. They are among the most commonly prescribed drugs worldwide. Contrary to early concerns over the carcinogenicity of statins, a growing body of evidence suggests statins may in fact have a chemopreventive potential against cancer. AREAS COVERED IN THIS REVIEW: In this paper, we review evidence on the association between statin use and cancer risk. Specifically, we report on clinical trials and observational studies that measured all cancer or site-specific cancers of the breast, colorectal, lung, prostate and reproductive organs associated with statin use. WHAT THE READER WILL GAIN: An understanding of the evidence, including strengths and limitations, to support an association between statins and cancer. Information on the current state of the field and future directions are also discussed. TAKE HOME MESSAGE: Few strong or consistent associations between statins and cancer incidence overall or for any of the sites reviewed were detected. Data for any effects of statins on cancer prognosis and secondary prevention are lacking; with the exception of consistent evidence that statins are associated with reduced risk of advanced/aggressive prostate cancer. Statins appear safe in relation to cancer risk but any chemopreventive effect in humans remains to be established and should not be recommended outside the context of clinical trials. It is encouraging that numerous trials are ongoing. The prospect of reducing the incidence and burden of some of the most prevalent cancers with safe, affordable and tolerable medication that already reduces the risk of the leading cause of death and cardiovascular disease warrants further exploration in clinical trials and observational studies of prognosis and survival.

Indexed as

AnimalsAnticarcinogenic AgentsBreast NeoplasmsColorectal NeoplasmsEndometrial NeoplasmsFemaleGallbladder DiseasesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLung NeoplasmsMaleNeoplasmsOvarian NeoplasmsProstatic NeoplasmsRandomized Controlled Trials as TopicRisk FactorsAnticarcinogenic AgentsHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID20377474
PMCPMC2910322
OpenAlexW2072073513

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.